SENL103 / SenlangBio - LARVOL DELTA

Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma. (PubMed, Blood Adv) - P=N/A | "We explored the use of nanobody-based BCMA(S103) CAR-T cell therapy for R/R plasma cell myeloma (NCT04447573). The one-year OS rate was 61.1%, and PFS was 57.2%. BCMA CAR-T therapy, utilizing dual nanobody VHHs targeting BCMA, demonstrates a high overall response rate (ORR) and manageable safety profile in treating patients with R/R plasmacytic myeloma, including those with high-risk features such as extramedullary lesions, high-risk cytogenetic abnormalities, plasma cell leukemia, or anaplastic plasmacytoma."

IO biomarker • Journal • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia • Plasmacytoma • TP53

Rosemary Collaboratory: A Policy, Systems, and Environmental Approach to Understanding and Addressing Health Inequities for People With Intellectual and Developmental Disabilities, United States. (PubMed, Am J Public Health) - "2026; 116(S2):S103-S111. https://doi.org/10.2105/AJPH.2026.308452)."

Journal • CNS Disorders • Developmental Disorders • Psychiatry

Robust adaptive H∞ fault-tolerant predictive control for air-ground integrated highway emergency self-organizing network systems based on RBF-DNN approximation. (PubMed, ISA Trans) - "Simulation results show that, under sudden link interruptions, 40-50 % packet loss and 75 % actuator performance degradation, the proposed controller maintains QoS and prescribed γ-level H∞ performance with asymptotic state convergence. On a real S103 highway dataset (372 samples, 10.8 % positives), the associated accident risk prediction module achieves 70-75 % test accuracy with PR-AUC is 0.683 and ROC-AUC is 0.715, demonstrating practically useful high-risk segment discrimination under severe class imbalance and confirming the engineering feasibility of the proposed control prediction framework."

Journal

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

BLESSING—Ⅰ: An open-label, single-arm Phase I clinical study of SENL103 autologous T-cell injection (S103) for the treatment of refractory generalized myasthenia gravis (ChiCTR) - P1 | N=18 | Not yet recruiting | Sponsor: Tangdu Hospital, the Fourth Military Medical University; Tangdu Hospital, the Fourth Military Medical University

New P1 trial • CNS Disorders • Myasthenia Gravis

On November 11, 2025, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that the Investigational New Drug (IND) application for "SENL103 Autologous T Cell Injection"...was accepted by the CDE again (Acceptance No.: CXSL2500958), and its indication is systemic light chain (AL) amyloidosis .

New trial • Amyloidosis

PKC?-mediated regulation of RIPK4 in keratinocyte differentiation (ESDR 2025) - "Phosphomutants were used in NF-κB and IRF6 reporter assays in HEK293T cells, where two sites, S103 and T283, displayed RIPK4 biological function despite lacking hyperphosphorylation on western blot. ATPγS kinase assays confirmed RIPK4 kinase activity is essential, but autophosphorylation is dispensable, suggesting alternative activation mechanisms. Our findings challenge the current model by showing that PKCη negatively regulates RIPK4 and keratinocyte differentiation, and that RIPK4 activation is independent of autophosphorylation, emphasizing the complexity of RIPK4 signaling and warranting further investigation into its upstream regulation."

IRF6

S-103: Cardiovascular implications of sleep disruption in women: Emerging evidence and clinical implications (WSS 2025) - No abstract available

Clinical • Cardiovascular • CNS Disorders • Sleep Disorder

s103: Diffuse large B cell lymphoma (DLBCL) (EHA 2025) - No abstract available

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

s103: Workshop: Crisis in Hematology in Ukraine (EHA 2025) - No abstract available

Hematological Disorders

The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Ting Chang, MD

New P1 trial • CNS Disorders • Myasthenia Gravis

the Safety and Efficacy of SENL103 Autologous T Cell Injection (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology